Grafa News and Videos — Page 436

Artelo Biosciences (NASDAQ:ARTL) reported new nonclinical data showing ART27.13 reduced neuropathic pain-associated behaviors in a paclitaxel-induced peripheral neuropathy model in male and female animals.

BioMarin Pharmaceutical (NASDAQ:BMRN) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for full approval of VOXZOGO (vosoritide) in children with achondroplasia, with an FDA decision target date of February 28, 2027.

Virtus Investment Partners (NYSE:VRTS) reported preliminary assets under management of $152.2 billion and other fee-earning assets of $1.7 billion, bringing total client assets to $153.9 billion as of June 30, 2026.

Voyager Therapeutics (NASDAQ:VYGR) reported six-month toxicology results for VY1706, its investigational tau-targeted gene therapy for Alzheimer’s disease, showing s

Edgewise Therapeutics (NASDAQ:EWTX) completed the sale of sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash and up to $1.1 billion in potential regulatory and commercial milestones.

Clearmind Medicine (NASDAQ:CMND) shared early insights from its ongoing Phase I/IIa trial of CMND-100, an investigational MEAI-based compound being evaluated for alcohol use disorder, following a June 10 webinar with study investigators from Yale and Johns Hopkins.

SLB (NYSE:SLB) announced that its OneSubsea joint venture was awarded a major engineering, procurement and construction contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire, covering subsea production systems for 13 wells.

Third Coast Bancshares (NYSE:TCBX) completed the sale of substantially all assets of its subsidiary Third Coast Commercial Capital to Gulf Coast Bank & Trust for approximately $27.5 million, generating a $3.5 million gain.

Aethlon Medical (NASDAQ:AEMD) reported that patients in the second cohort of its oncology feasibility study exhibited biological changes.

Diana Shipping (NYSE:DSX) extended its tender offer to acquire all outstanding shares of Genco Shipping & Trading (NYSE:GNK) it does not already own through July 24, 2026, after shareholders tendered 11.08 million shares.